復星醫藥(02196.HK)子公司注射用尼可地爾用於治療不穩定型心絞痛的藥品註冊申請獲審評受理
格隆匯3月10日丨復星醫藥(02196.HK)公佈,公司控股子公司重慶藥友製藥有限責任公司自主研發的注射用尼可地爾用於治療不穩定型心絞痛的藥品註冊申請於近期獲國家藥品監督管理局審評受理。
該新藥為集團自主研發的化學藥品,擬主要用於治療不穩定型心絞痛。
截至本公吿日,於中國境內(不包括港澳台地區,下同)已獲批上市的注射用尼可地爾包括北京四環科寶製藥股份有限公司的瑞科喜和揚子江藥業集團有限公司的注射用尼可地爾。根據IQVIACHPA最新數據(由IQVIA提供,IQVIA是全球領先的醫藥健康產業專業信息和戰略諮詢服務提供商;IQVIACHPA數據代表中國境內100張牀位以上的醫院藥品銷售市場,不同的藥品因其各自銷售渠道佈局的不同,實際銷售情況可能與IQVIACHPA數據存在不同程度的差異),2022年度,注射用尼可地爾於中國境內的銷售額約為人民幣11.56億元。
截至2023年2月,集團現階段針對該新藥累計研發投入約為人民幣421萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.